Korlym Can Cause Both Leg Pain and Shortness of Breath
Yes, both burning/stinging sensations in the legs and shortness of breath are recognized side effects of Korlym (mifepristone), though they occur through different mechanisms and with varying frequency.
Leg Pain and Burning Sensations
According to the FDA drug label, pain in extremities (legs and arms) occurred in 12% of patients taking Korlym 1. The broader category of "arthralgia" (joint pain) was even more common at 30% 1. While the FDA label describes this as "pain in extremity" rather than specifically "burning or stinging," musculoskeletal symptoms affecting the legs are well-documented adverse effects.
Key Points About Leg Symptoms:
- Pain in extremities: 12% of patients
- Arthralgia: 30% of patients
- Myalgia (muscle pain): 14% of patients
- These symptoms were common enough to cause dose interruption or reduction in 40% of patients 1
Shortness of Breath (Dyspnea)
Dyspnea (shortness of breath) occurred in 16% of patients in clinical trials 1. This is a significant and potentially serious side effect that requires careful evaluation.
Critical Consideration - Pneumocystis Infection:
The FDA label includes a specific warning that patients with Cushing's syndrome taking Korlym are at risk for opportunistic infections such as Pneumocystis jiroveci pneumonia, and patients may present with respiratory distress shortly after initiation of Korlym 1. This is particularly important because:
- Patients with endogenous Cushing's syndrome have compromised immune function
- Respiratory symptoms warrant immediate diagnostic evaluation
- Treatment for Pneumocystis should be considered if respiratory distress develops 1
Clinical Management Recommendations
If you are experiencing these symptoms while taking Korlym:
Contact your prescribing physician immediately - especially regarding shortness of breath, as this requires urgent evaluation to rule out serious causes including opportunistic infection
Do not discontinue the medication without medical guidance - Korlym has a long half-life and stopping it abruptly may require several days of stress-dose glucocorticoid replacement 2
Monitor for other concerning symptoms including:
- Fatigue, nausea, or weakness (possible adrenal insufficiency)
- Worsening respiratory symptoms
- Fever or signs of infection
Important Caveats:
The guidelines emphasize that mifepristone should only be used by clinicians with extensive experience in Cushing's disease 2, as monitoring is complex and cortisol levels cannot be reliably used to assess treatment adequacy or safety. The combination of leg symptoms and respiratory symptoms warrants thorough evaluation to distinguish between:
- Expected medication side effects
- Adrenal insufficiency from overtreatment
- Opportunistic infection (particularly with respiratory symptoms)
- Other unrelated medical conditions
Your symptoms fall within the documented adverse effect profile of Korlym, but shortness of breath specifically requires prompt medical evaluation to ensure patient safety 1.